Blog
Build relationships, have fun & make a difference in the Guelph PKD community!

Join the PKD Foundation of Canada’s Guelph Walk to END PKD team as we spread awareness, support PKD patients and make a difference in our community.

Our Walk to END PKD signifies a united group, moving towards treatment and a cure for polycystic kidney disease (PKD).

You can make a positive impact on all those affected by this disease by signing up as a volunteer at this year’s Guelph Walk to END PKD – taking place on Sunday, September 8, 2019! 

Sign up to become a volunteer below!

Meet Your Walk Coordinator

 Meet Carrie Manson

Carrie is the Guelph Walk Coordinator. Her husband, John was diagnosed with PKD in 2010 after his father, Jim, passed away from kidney disease in 2009, at the age of 59. John's brother is also affected by PKD. Carrie and her family are committed to helping find a cure for PKD and advocating for all those affected by this disease.

Read Carrie and her husband's interview with the Guelph Mercury Tribune here

Become a volunteer

2017 Canadian PKD Symposium is Now Online

On November 25, 2017 we held our biennial Canadian PKD Symposium, which included participants from the PKD medical community and various renal healthcare centres, as well as PKD patients, their families and loved ones.

The New England Journal of Medicine Publishes Phase 3 Results for Tolvaptan in Patients with ADPKD

We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference in New Orleans and published online in the New England Journal of Medicine.

Large Tolvaptan Trial Results Show Positive Future for ADPKD Patients

We are glad to share some great news for the Canadian PKD community, as tolvaptan receives positive results from an additional one year international trial. The trial outcome was positive for tolvaptan in the treatment of ADPKD. Also of note, the trial had participation from Canadian patients and nephrologists.